137 related articles for article (PubMed ID: 12889215)
1. Assessment of vascular involvement.
Kahaleh B; Meyer O; Scorza R
Clin Exp Rheumatol; 2003; 21(3 Suppl 29):S9-14. PubMed ID: 12889215
[TBL] [Abstract][Full Text] [Related]
2. Assessment of lung involvement.
Matucci-Cerinic M; D'Angelo S; Denton CP; Vlachoyiannopoulos P; Silver R
Clin Exp Rheumatol; 2003; 21(3 Suppl 29):S19-23. PubMed ID: 12889217
[TBL] [Abstract][Full Text] [Related]
3. Assessment of gastrointestinal involvement.
Clements PJ; Becvar R; Drosos AA; Ghattas L; Gabrielli A
Clin Exp Rheumatol; 2003; 21(3 Suppl 29):S15-8. PubMed ID: 12889216
[TBL] [Abstract][Full Text] [Related]
4. Vascular complications of scleroderma.
Guiducci S; Giacomelli R; Cerinic MM
Autoimmun Rev; 2007 Sep; 6(8):520-3. PubMed ID: 17854742
[TBL] [Abstract][Full Text] [Related]
5. Assessment of kidney involvement.
Steen VD; Mayes MD; Merkel PA
Clin Exp Rheumatol; 2003; 21(3 Suppl 29):S29-31. PubMed ID: 12889219
[TBL] [Abstract][Full Text] [Related]
6. Assessment of disease activity.
Valentini G; Silman AJ; Veale D
Clin Exp Rheumatol; 2003; 21(3 Suppl 29):S39-41. PubMed ID: 12889221
[TBL] [Abstract][Full Text] [Related]
7. Capillaroscopic findings in systemic sclerosis -- are they associated with disease duration and presence of digital ulcers?
Lambova S; Müller-Ladner U
Discov Med; 2011 Nov; 12(66):413-8. PubMed ID: 22127112
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: Clinical and prognostic implications.
Ghizzoni C; Sebastiani M; Manfredi A; Campomori F; Colaci M; Giuggioli D; Ferri C
Microvasc Res; 2015 May; 99():92-5. PubMed ID: 25842153
[TBL] [Abstract][Full Text] [Related]
9. A Delphi exercise and cluster analysis to aid in the development of potential classification criteria for systemic sclerosis using SSc experts and databases.
Coulter C; Baron M; Pope JE
Clin Exp Rheumatol; 2013; 31(2 Suppl 76):24-30. PubMed ID: 23557780
[TBL] [Abstract][Full Text] [Related]
10. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
11. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis.
Zulian F; Woo P; Athreya BH; Laxer RM; Medsger TA; Lehman TJ; Cerinic MM; Martini G; Ravelli A; Russo R; Cuttica R; de Oliveira SK; Denton CP; Cozzi F; Foeldvari I; Ruperto N
Arthritis Rheum; 2007 Mar; 57(2):203-12. PubMed ID: 17330294
[TBL] [Abstract][Full Text] [Related]
12. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
13. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry.
Khimdas S; Harding S; Bonner A; Zummer B; Baron M; Pope J;
Arthritis Care Res (Hoboken); 2011 Jan; 63(1):142-9. PubMed ID: 20740608
[TBL] [Abstract][Full Text] [Related]
14. Best practices in scleroderma: an analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG).
Harding S; Khimdas S; Bonner A; Baron M; Pope J;
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S38-43. PubMed ID: 22691207
[TBL] [Abstract][Full Text] [Related]
15. Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders.
Maricq HR; Weinrich MC; Valter I; Palesch YY; Maricq JG
J Rheumatol; 1996 Dec; 23(12):2068-78. PubMed ID: 8970043
[TBL] [Abstract][Full Text] [Related]
16. Advances in the diagnosis and management of scleroderma-related vascular complications.
Kerin K; Yost JH
Compr Ther; 1998; 24(11-12):574-81. PubMed ID: 9847974
[TBL] [Abstract][Full Text] [Related]
17. Application of the 2013 ACR/EULAR classification criteria for systemic sclerosis to patients with Raynaud's phenomenon.
Park JS; Park MC; Song JJ; Park YB; Lee SK; Lee SW
Arthritis Res Ther; 2015 Mar; 17(1):77. PubMed ID: 25889905
[TBL] [Abstract][Full Text] [Related]
18. The challenge of establishing treatment efficacy for cutaneous vascular manifestations of systemic sclerosis.
Pauling JD
Expert Rev Clin Immunol; 2018 May; 14(5):431-442. PubMed ID: 29641934
[TBL] [Abstract][Full Text] [Related]
19. 2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group.
Alhajeri H; Hudson M; Fritzler M; Pope J; Tatibouet S; Markland J; Robinson D; Jones N; Khalidi N; Docherty P; Kaminska E; Masetto A; Sutton E; Mathieu JP; Ligier S; Grodzicky T; LeClercq S; Thorne C; Gyger G; Smith D; Fortin PR; Larché M; Baron M
Arthritis Care Res (Hoboken); 2015 Apr; 67(4):582-7. PubMed ID: 25233870
[TBL] [Abstract][Full Text] [Related]
20. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
